Insomnia

• What are Therapeutic Market Outlooks?
• Available Reports
• Pricing and Deliverables
• TMO Sample Pages

Tables and Figures - Insomnia

• Page 4: National Institutes of Health (NIH) Insomnia Classifications
• Page 5: Theoretical Patient Population Breakdown by Severity and Duration of Insomnia
• Page 6: Theoretical Patient Population Breakdown by Sub-type of Insomnia, Theoretical Patient Population Breakdown - Patient Interface with Healthcare System
• Page 8: Insomnia Patient Population Model, AVOS Insomnia Population Projections by Year
• Page 12: U.S. Insomnia Market Model, 2004-2013
• Page 13: U.S. Insomnia Market Model, 2004-2013, continued
• Page 14: The Diagnostic Approach to Insomnia
• Page 15: Insomnia Treatment Algorithm
• Page 18: AVOS Physician Panel Product Ratings
• Page 20: Marketed Products in the United States
• Page 21: Benzodiazpines Used in the Treatment of Insomnia, Timeline of Major Insomnia Market Events
• Page 24: Insomnia Clinical Trial Efficacy Endpoints
• Page 25: Forecasts of Future Market Trends
• Page 26: Ambien/Ambien CR Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 28: Zolpidem/Zolpidem CR Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 30: Sonata/zaleplon Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 32: Lunesta/eszopiclone Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 34: Rozerem Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 36: Restoril/temazepam Revenue Model, U.S. Market Share Forecasts, U.S. Revenue Forecasts, and Commercial Strength
• Page 38: Indiplon Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 40: Silenor Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 42: Eplivanserin/Volinanserin Revenue Models, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 44: ORG 50081 Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 46: Almorexant Revenue Model, U.S. Market Share Forecasts, and U.S. Revenue Forecasts
• Page 48: Clinical Success Rates of Insomnia Agents: 1990-Present
• Page 50: Drugs in Development